ArticleJACC. Asia2026
Physiological Patterns of Coronary Artery Disease and Drug-Coated Balloon Performance.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug-Coated Balloon for Diffuse Coronary Artery Disease.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse coronary artery disease (CAD) challenges stent-based percutaneous coronary intervention (PCI). Drug-coated balloons (DCBs) offer a stentless strategy, but the physiological response in focal compared with diffuse disease remains unclear.
objectivesThe authors aimed to investigate the impact of physiological patterns on angiographic and physiological outcomes after DCB-PCI.
methodsIn this international cohort, patients underwent DCB-PCI for de novo lesions with angiographic follow-up at 5 months (IQR: 3-7). Quantitative coronary angiography and Murray's law-based quantitative flow ratio (μFR) were analyzed by a core laboratory. Virtual μFR pull backs generated the pull back pressure gradient index (PPGi), classifying disease as focal (PPGi ≥0.78) or diffuse (PPGi <0.78).
resultsAmong 230 patients/lesions, 139 of 230 (60.4%) were focal and 91 of 230 (39.6%) diffuse. Baseline μFR was comparable between diffuse and focal disease (0.64 [0.45-0.80] vs 0.61 [0.32-0.79]; P = 0.21). After PCI, diffuse disease showed lower acute functional gain (ΔμFR 0.23 [0.09-0.36] vs 0.29 [0.12-0.51]; P = 0.03), lower post-PCI μFR (0.89 [0.82-0.93] vs 0.91 [0.86-0.94]; P = 0.03), and more suboptimal physiology (19 of 91, 20.9% vs 12 of 139, 8.6%; P = 0.01). At follow-up, late functional loss was minimal and similar (+0.01 [-0.04 to 0.06] vs -0.01 [-0.04 to 0.04]; P = 0.53), yet diffuse CAD maintained lower μFR (0.88 [0.78-0.93] vs 0.91 [0.85-0.95]; P = 0.03) and more ischemic physiology (27 of 91, 29.7% vs 16 of 139, 11.5%; P = 0.01).
conclusionsPPGi stratifies outcomes after DCB-PCI: diffuse CAD shows smaller acute μFR gain and more suboptimal post-PCI physiology, despite minimal late angiographic and functional loss, highlighting the importance of optimal acute physiological results, particularly in diffuse disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.